FDA approves Benlysta autoinjector for pediatric patients with active lupus nephritis
The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving standard therapy.
Jul 1, 2025
0
0








